Tim Opler
PersonTim Opler is a biotech investment banker and Managing Director in Stifel's Global Healthcare Group, where he leads strategic and financing transactions across healthcare sectors. He is known for advising life sciences companies and commenting on developments in the biopharmaceutical industry.
Email alert
Email me when Tim Opler comes up on a podcast
One email a week at most, with the new episodes that mention Tim Opler. Free, no account needed, unsubscribe in one click.
What Tim Opler has said on podcasts
5 statements
AI will substantially drive efficiency in biotech.
“AI is going to be a big, big factor kind of driving efficiencies.”
Open the episode · Episode 201 - October 30, 2026Listen at 9:07
Clinical development, not target identification or design, is drug development’s main bottleneck.
“the real bottleneck in drug development isn't sort of, target identification, you know, drug design, the bottleneck is clinical development.”
Open the episode · Episode 201 - October 30, 2026Listen at 17:51
AI efficiencies will be meaningful but will not accelerate drug development by 90%.
“I think the efficiencies that it will bring. be meaningful, but more marginal and certainly not accelerate things by 90%.”
Open the episode · Episode 201 - October 30, 2026Listen at 18:23
Statements are attributed to the speaker as said on the episode and reflect their view at the time, not PodLume's. They are not advice.